CDK4 and acral lentiginous melanoma: This may serve as a cautionary note for the identification of ALM patients who may benefit from CDK4i/6i based solely on tumor sequencing, which may prevent patients with elevated CDK4/CDK6 protein expression but no clear evidence of copy number variation in CDK4/6 pathway genes from treatment.